These include Ruxolitinib, a janus kinase 1/2 inhibitor for Primary Myelofibrosis and Polycythemia Vera [12], Ibrutinib, a bruton kinase inhibitor for B-cell malignancies [13] and most recently Midostaurin, a multi-kinase inhibitor for FMS-like tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML) [14, 15]. This evidence concerns the gene FLT3 and acquired polycythemia vera.